Citi lowered the firm’s price target on Pliant Therapeutics (PLRX) to $1.50 from $4 and keeps a Neutral rating on the shares. The company ...

While architectural, museum-worthy nail art is a delight to behold and just as fun to wear, some folks are in the camp of ...

As Meghan’s new Netflix show airs for the first time, Tanya Gold explores the complex, heartbreaking and deeply unhealthy ...